When and How Should Active Surveillance for Prostate Cancer be De-Escalated?
- PMID: 32019719
- PMCID: PMC7394715
- DOI: 10.1016/j.euf.2020.01.001
When and How Should Active Surveillance for Prostate Cancer be De-Escalated?
Abstract
Despite widespread adoption of active surveillance (AS) for low-risk prostate cancer, less is known about how or when monitoring should be deintensified. We performed a narrative review of the available evidence and guidelines addressing transitions from active to passive monitoring, including watchful waiting. Increasing age and comorbidity limit quality-adjusted life years gained from curative intervention, although no universal thresholds exist to denote a transition from active monitoring. Despite observational studies indicating that AS intensity decreases over time, the risk of distant progression also increases with age, suggesting an opportunity to improve decision support that incorporates multiple factors when navigating these decisions. PATIENT SUMMARY: We reviewed the available evidence surrounding transitioning from active monitoring to observation. Clinical practice guidelines and research studies support decreasing intensity based on an appreciation of age, other medical problems, and patient preferences.
Keywords: Active surveillance; Monitoring; Prostate cancer; Transition; Watchful waiting.
Copyright © 2020 European Association of Urology. All rights reserved.
References
-
- Mottet N, van den Bergh RCN, Briers E, et al. EAU-ESTRO-EANM-ESUR-SIOG guidelines on prostate cancer 2019. Vol. European Association of Urology Guidelines 2019 Ed. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2019.
-
- National Comprehensive Cancer Network. Prostate cancer (version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf
-
- Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J. Quantifying the transition from active surveillance to watchful waiting among men with very low-risk prostate cancer. Eur Urol 2017;72:534–41. - PubMed
-
- de Carvalho TM, Heijnsdijk EAM, de Koning HJ. When should active surveillance for prostate cancer stop if no progression is detected? Prostate 2017;77:962–9. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
